Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL WITH CALCIUM COPACKAGED versus IBANDRONATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL WITH CALCIUM COPACKAGED versus IBANDRONATE SODIUM.
ACTONEL WITH CALCIUM (COPACKAGED) vs IBANDRONATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and interfering with the mevalonate pathway, leading to loss of osteoclast activity and induction of apoptosis.
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
150 mg orally once monthly for osteoporosis; 3 mg intravenously over 15-30 seconds every 3 months for osteoporosis; 6 mg intravenously over 15-30 minutes for metastatic bone disease (repeat every 3-4 weeks).
None Documented
None Documented
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Terminal elimination half-life ranges from 10 to 60 hours, with a mean of approximately 37 hours; due to high affinity for bone, the drug is slowly released from bone compartment, resulting in an extended terminal half-life of up to 90-160 hours in bone; clinical context: supports once-monthly oral dosing and once-every-3-months intravenous dosing for osteoporosis.
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 mL/min.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion; approximately 50-60% of absorbed dose is excreted unchanged in urine within 24 hours, with cumulative urinary excretion accounting for 50-80% of systemically absorbed dose; non-renal clearance (biliary/fecal) is negligible (<1%).
Category C
Category D/X
Bisphosphonate and Calcium Supplement
Bisphosphonate